Lee JC, Hung J-Y, Kim Y-C, Chang G-C, Yoo S, Yang S-H, Davis K, Nagar S, Taylor A, Lee S, Shih J-Y. Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan. apjcb [Internet]. 20May2021 [cited 4Dec.2023];6(2):123-32. Available from: http://waocp.com/journal/index.php/apjcb/article/view/663